Aug 28 (Reuters) - Moderna Inc MRNA.O said on Friday it was in talks with Japan's government to potentially supply 40 million or more doses of its COVID-19 vaccine candidate.
The vaccine candidate, mRNA-1273, would be supplied by Moderna and distributed in Japan by Takeda Pharmaceutical Co Ltd 4502.T, beginning in the first half of 2021, if it receives regulatory approval.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Ramakrishnan M.)
((email@example.com; +91 8061822700;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In This StoryMRNA
Latest Markets Videos
- Tesla removed from S&P 500 ESG index on autopilot, discrimination concerns
- Fed could cut rates in 2023, 2024 once inflation under control -Bullard
- US STOCKS-Wall Street ends sharply lower as Target and growth stocks sink
- Powell says Fed to 'keep pushing' rates higher until clear inflation is falling